Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand Up 2 cancer study-Reference-Cited by-同舟云学术

Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand Up 2 cancer study

Published:2017-02-05 Issue:21 Volume:8 Page:35326-35338
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Azad Nilofer S.¹,el-Khoueiry Anthony²,Yin Jun³,Oberg Ann L.³,Flynn Patrick⁴,Adkins Douglas⁵,Sharma Anup¹,Weisenberger Daniel J.²,Brown Thomas¹,Medvari Prakriti¹,Jones Peter A.⁶,Easwaran Hariharan¹,Kamel Ihab¹,Bahary Nathan⁷,Kim George⁸,Picus Joel⁵,Pitot Henry C.³,Erlichman Charles³,Donehower Ross¹,Shen Hui⁶,Laird Peter W.⁶,Piekarz Richard⁵,Baylin Stephen¹,Ahuja Nita¹

Affiliation:

1. Johns Hopkins University, Baltimore, MD, USA

2. University of Southern California, Los Angeles, CA, USA

3. Mayo Clinic, Rochestor, MN, USA

4. Metro-Minnesota CCOP, Minneapolis, MN, USA

5. Washington University, St. Louis, MO, USA

6. Van Andel Research Institute, Grand Rapids, MI, USA

7. University of Pittsburgh, Pittsburgh, PA, USA

8. Mayo Clinic, Jacksonville, FL, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. From Crypts to Cancer: A Holistic Perspective on Colorectal Carcinogenesis and Therapeutic Strategies;International Journal of Molecular Sciences;2024-08-30

2. Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer;Clinical Cancer Research;2024-01-17

3. Role of Histone Deacetylase 6 and Histone Deacetylase 6 Inhibition in Colorectal Cancer;Pharmaceutics;2023-12-29

4. Inappropriate Expression of PD-1 and CTLA-4 Checkpoints in Myeloma Patients Is More Pronounced at Diagnosis: Implications for Time to Progression and Response to Therapeutic Checkpoint Inhibitors;International Journal of Molecular Sciences;2023-03-17

5. Epigenetics in cancer development, diagnosis and therapy;Epigenetics in Health and Disease - Part B;2023